# Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

> **NCT01718353** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 63 (actual)

## Conditions studied

- Prostate Cancer Metastatic

## Interventions

- **DRUG:** DOCETAXEL (XRP6976)
- **DRUG:** CABAZITAXEL (XRP6258)
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT01718353
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2017-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01718353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01718353, "Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01718353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*